Search research articles
Contact Us
Filters
Showing results (11-20 of 56) with videos related to
Page
of 6
Sort By:
Biochemical Pharmacology
|
January 18, 2012
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance
Karthika Natarajan, Yi Xie, Maria R Baer, et al.
Statistics in Medicine
|
January 12, 2008
Experimental design and interaction analysis of combination studies of drugs with log-linear dose responses
Hong-Bin Fang, Douglas D Ross, Edward Sausville, et al.
Journal of Palliative Medicine
|
October 22, 2005
Long-term evaluation of required coursework in palliative and end-of-life care for medical students
Douglas D Ross, Deborah Shpritz, Margaret M Hull, et al.
Blood
|
March 18, 2006
Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression
Takeo Nakanishi, Ken Shiozawa, Bret A Hassel, et al.
Cancer Chemotherapy and Pharmacology
|
December 26, 2006
Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIPL
Tamer E Fandy, Douglas D Ross, Steven D Gore, et al.
Molecular Cancer Therapeutics
|
January 7, 2005
Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference
P L Rachel Ee, Xiaolong He, Douglas D Ross, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology
|
March 5, 2003
Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines
Thomas Efferth, Axel Sauerbrey, Marc-Eric Halatsch, et al.
Anticancer Research
|
January 30, 2003
Activity of ascaridol from the anthelmintic herb Chenopodium anthelminticum L. against sensitive and multidrug-resistant tumor cells
Thomas Efferth, Armin Olbrich, Axel Sauerbrey, et al.
Biochemical Pharmacology
|
June 1, 2010
Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors
Xuetao Fan, Douglas D Ross, Hiroshi Arakawa, et al.
Neoplasia (New York, N.Y.)
|
July 20, 2005
Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma
Tamer E Fandy, Sharmila Shankar, Douglas D Ross, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 56) with videos related to
Sort By:
Page
of 6
Biochemical Pharmacology
|
January 18, 2012
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance
Karthika Natarajan, Yi Xie, Maria R Baer, et al.
Statistics in Medicine
|
January 12, 2008
Experimental design and interaction analysis of combination studies of drugs with log-linear dose responses
Hong-Bin Fang, Douglas D Ross, Edward Sausville, et al.
Journal of Palliative Medicine
|
October 22, 2005
Long-term evaluation of required coursework in palliative and end-of-life care for medical students
Douglas D Ross, Deborah Shpritz, Margaret M Hull, et al.
Blood
|
March 18, 2006
Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression
Takeo Nakanishi, Ken Shiozawa, Bret A Hassel, et al.
Cancer Chemotherapy and Pharmacology
|
December 26, 2006
Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIPL
Tamer E Fandy, Douglas D Ross, Steven D Gore, et al.
Molecular Cancer Therapeutics
|
January 7, 2005
Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference
P L Rachel Ee, Xiaolong He, Douglas D Ross, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology
|
March 5, 2003
Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines
Thomas Efferth, Axel Sauerbrey, Marc-Eric Halatsch, et al.
Anticancer Research
|
January 30, 2003
Activity of ascaridol from the anthelmintic herb Chenopodium anthelminticum L. against sensitive and multidrug-resistant tumor cells
Thomas Efferth, Armin Olbrich, Axel Sauerbrey, et al.
Biochemical Pharmacology
|
June 1, 2010
Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors
Xuetao Fan, Douglas D Ross, Hiroshi Arakawa, et al.
Neoplasia (New York, N.Y.)
|
July 20, 2005
Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma
Tamer E Fandy, Sharmila Shankar, Douglas D Ross, et al.
Page
of 6